Chris Cargill appointed as President and Chief Executive Officer • Dr.

success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris

Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance

INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris

From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever

Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris

., Choi, H. J., Fung, J. J., Pardon, E., Casarosa, P., Chae, P. S., Devree, B. T., Rosenbaum, D.